logo
Man with stage 4 cancer beats rare mutation in Gurgaon

Man with stage 4 cancer beats rare mutation in Gurgaon

Time of India4 hours ago

Gurgaon:
Cancer is a relentless enemy but not an invincible one, says Dr Pooja Babbar, under whose watch a 38-year-old man with a rare and aggressive head and neck cancer has made a remarkable recovery.
Tired of too many ads? go ad free now
The patient with Stage 4 mucoepidermoid carcinoma battled the disease for over two years, with no success from surgeries or conventional chemotherapy at a Jaipur-based hospital.
But doctors under the care of Babbar — consultant and unit head, medical oncology at Fortis Hospital, Manesar — treated the patient, who has now beaten the disease after receiving advanced targeted therapy. Entrectinib, an oral targeted therapy, attacks cancer cells based on their genetic profile.
Dr Babbar told TOI, "Oral targeted therapies offer a focused approach by attacking specific molecules in cancer cells, reducing damage to healthy tissue. In this case, the treatment led to a dramatic reduction — around 60–70% — in tumour size within two months and near-complete regression by the fourth month."
Earlier this year, when the man had arrived at Fortis Hospital, the cancer progressed significantly, with a large tumour causing visible disfigurement on the right side of his face and neck and spreading to his lungs, doctors said.
The patient was in severe pain, experienced significant weight loss and was emotionally distressed.
Under the care of Babbar, the patient was assessed using next generation sequencing (NGS), a form of molecular testing that revealed a rare gene mutation found in fewer than 1% of cancer cases. This finding enabled doctors to shift from conventional chemotherapy to a personalised treatment plan using Entrectinib.
Tired of too many ads? go ad free now
Despite the advanced stage of the disease, the personalised therapy not only halted the cancer's progression but also brought visible and measurable improvement in a short period. He is now stable and continues to undergo maintenance therapy with regular follow-ups.
Dr Babbar laid stress on the importance of timely diagnosis and genetic profiling in delivering effective cancer treatment. "If there was further delay in personalised intervention, his survival chances would have declined drastically," she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SpaceX Launches Dog's Ashes To Space On Memorial Flight
SpaceX Launches Dog's Ashes To Space On Memorial Flight

NDTV

time28 minutes ago

  • NDTV

SpaceX Launches Dog's Ashes To Space On Memorial Flight

A dog's ashes were among the remains sent into space this weekend as part of a memorial mission honouring loved ones by carrying them beyond Earth's atmosphere. Franz, a beloved family Labrador, was among 166 small capsules launched aboard the inaugural Perseverance SpaceX Flight by Texas-based Celestis Inc. The mission lifted off Sunday around 5:30 pm from Vandenberg Space Force Base in Santa Barbara, California. Franz died aged 13 in October 2020. "He was the best dog, just so soft and nice and loved hugs," said the dog's owner Harvin Moore. The pet was more like a sibling to Mr Moore's children, Elizabeth and Quinn. "Now we can't wait to watch our good boy go galactic," he told The NY Post ahead of the launch. The flight lasted about three hours, during which the capsules orbited Earth twice. The rocket then re-entered the atmosphere and splashed down in the Pacific Ocean somewhere between Alaska and Hawaii. A recovery ship, stationed at sea ahead of time, tracked and retrieved the capsules before sending them to Germany for processing. Within two months, the remains will be returned to their families. The cost to send each capsule into space was $3,500 (over Rs 3 lakh). For Franz's owner, the expense was "a lot more" than the dog's value, but entirely worth it for his family of space enthusiasts. Mr Moore said, "The emotional power of being with a group of people who are celebrating the life of a loved one in this way ... it's amazing. It's nothing we'll ever forget. It's just pure joy." Houston-based Celestis has a long history of sending DNA and cremated remains of people, pets, and celebrities into space using rockets like United Launch Alliance's Vulcan Centaur. Their missions have carried iconic figures such as "Star Trek" legends Nichelle Nichols, DeForest Kelley, Gene Roddenberry and his wife Majel Barrett Roddenberry, and James "Scotty" Doohan. They also flew Douglas Trumbull, a visual effects pioneer behind 2001: A Space Odyssey and Close Encounters of the Third Kind, along with symbolic remains of four former US presidents, George Washington, Dwight D Eisenhower, John F Kennedy, and Ronald Reagan, on last year's deep-space Enterprise Flight. Each capsule, crafted from titanium or aluminium and measuring roughly a quarter to half an inch, contained either DNA or cremated remains. These precious capsules orbited Earth twice aboard a 23-foot-tall SpaceX Falcon 9 rocket, travelling at a speed of almost 28,000 kmph in low Earth orbit. Charles Chafer, Celestis CEO and co-founder said Saturday, "Many people whose ashes and DNA are flying are people that always wanted to go to space in their lifetime but were never able to do that. It also helps families move from feelings of grief to joy." Also aboard the Perseverance Flight were the ashes of Wesley Dreyer, an aerospace engineer involved in investigating the 1986 Space Shuttle Challenger disaster, as well as the DNA of a living three-year-old boy in Germany.

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3
Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

Business Standard

time32 minutes ago

  • Business Standard

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

US-based pharmaceutical company Eli Lilly on Monday announced findings from the Phase 3 clinical trials for its once-weekly investigational insulin drug, efsitora alfa (efsitora), indicating positive safety and efficacy results for A1C reduction compared to daily basal insulin. While basal insulin is a long-acting insulin administered once or twice a day, efsitora is designed for once-weekly subcutaneous injection. The company also shared detailed results from the Phase 3 QWINT-1, QWINT-3 and QWINT-4 trials. The QWINT-1 trial evaluated adults initiating insulin therapy, while QWINT-3 assessed individuals previously using daily basal insulin. QWINT-4 included participants using both basal and mealtime insulin. 'In each study, efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin,' the company stated. According to Lilly, in QWINT-1, efsitora reduced A1C by 1.31 per cent compared to 1.27 per cent for insulin glargine at week 52 for the efficacy estimand. In QWINT-3, the drug reduced A1C by 0.86 per cent compared to 0.75 per cent for insulin degludec at week 26. 'In QWINT-4, efsitora reduced A1C by 1.07 per cent, matching insulin glargine's reduction of 1.07 per cent at week 26 for the efficacy estimand,' Lilly added. The Phase 3 global clinical development programme for the diabetes drug began in 2022 and included over 3,000 participants with type 2 diabetes across four global registration studies. Commenting on the results, Jeff Emmick, senior vice president of product development at Lilly, said that the once-weekly insulin therapy may offer a significant advancement for people with type 2 diabetes who need insulin, by eliminating over 300 injections a year. The company added that the drug also has the potential to provide more stable glucose levels—reducing glucose variability—throughout the week. Eli Lilly now plans to submit the drug to global regulatory agencies for the treatment of type 2 diabetes in adults by the end of 2026.

Andhra woman becomes first Indian to complete Nasa program, to go to space in 2029
Andhra woman becomes first Indian to complete Nasa program, to go to space in 2029

India Today

time2 hours ago

  • India Today

Andhra woman becomes first Indian to complete Nasa program, to go to space in 2029

Dangeti Jahnavi from Palakollu in Andhra Pradesh's West Godavari district is set to travel to space in 2029. A graduate in Electronics and Communication Engineering, Jahnavi holds the distinction of being the first Indian to successfully complete NASA's prestigious International Air and Space has been selected to travel to the Titan's Orbital Port Space Station, a US-based project slated for inauguration in the next four space enthusiast completed her undergraduate studies at Lovely Professional University in Punjab, after finishing her Intermediate education in her hometown of Palakollu. Her parents, Srinivas and Padmasri, currently reside in Kuwait for work. Jahnavi is known for her active engagement in the field of STEM education and space outreach. She has delivered talks for ISRO's educational programs and addressed students at premier institutions including National Institutes of Technology (NITs) across the country. She also regularly takes part in analog missions, deep-sea diving, and global conferences related to planetary science and sustainability in long-duration space contributions to the International Astronomical Search Collaboration led to a provisional asteroid discovery, based on data from the Panoramic Survey Telescope and Rapid Response System (Pan-STARRS). She was also the youngest foreign analog astronaut and the first Indian chosen for Space Iceland's geology the years, Jahnavi has been recognised with numerous accolades including the People's Choice Award at the NASA Space Apps Challenge and the ISRO World Space Week Young Achiever Award.- Ends IN THIS STORY#Andhra Pradesh

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store